Passionate about helping to shape and direct the future of healthcare.
Professor Stephen Worthley is the Executive Manager of Cardiology at GenesisCare, having been in the role for four years and in the GenesisCare network as an Interventional Cardiologist for 13 years. Stephen has recently taken an expanded role as Lead for the Australian Integrated Cancer Care Program, the program will work with various clinical treatment services, to provide a comprehensive cancer care for our patients. Stephen will also continue in his role leading the Cardiology business.
Stephen’s passion is evident in the work he does as a renowned Interventional Cardiologist, with a special interest in Transcatheter Aortic Valve Replacement (TAVR). In May 2019, Stephen participated in a world first transcatheter mitral valve replacement procedure, implanting an artificial valve in a patient’s heart without invasive open-heart surgery.
Stephen graduated from Medicine at the Adelaide University, South Australia. His training included a Cardiology fellowship at the Royal Adelaide Hospital, his PhD at the Mount Sinai Medical Centre in New York, and post-doctoral research and interventional fellowship at Monash Medical Centre, Melbourne. He established the first dedicated Cardiac CT and MR units in the Asia Pacific region, as well as leading the Cardiovascular Research Centre at the University of Adelaide as the Helpman Professor of Cardiovascular Medicine, a position he held between 2004 to 2016.
Stephen was integral in forming a radial access program at the Royal Adelaide Hospital, which developed into the largest volume radial access program in Australia. He is also renowned for his academic work in cardiac imaging and interventional techniques. He regularly teaches and trains cardiology fellow students in interventional therapies and was a proctor for TAVR across Europe and North America.
He has published over 200 manuscripts, 5 book chapters, and co-edited a Cardiovascular Textbook. He leads a number of novel international multi-centre cardiovascular therapy trials, and his clinical and research expertise spans natriuretic peptide and stem cell therapies though to transcatheter valve implantation and renal artery denervation therapy. He sits on numerous industry advisory boards, journal editorial boards and government advisory groups.